Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05454267

Early Detection of Vaping-related Vascular Diseases

The purpose of this study is to determine how vaping affects blood vessels, in particular if early damage occurs in the lung vessels.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Vaping Behavior Blood Vessel Injury Cardiovascular Diseases Smoking Vascular Diseases Vascular System Injuries Wounds and Injuries

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Miami Health System

Miami, Florida, 33136, United States

Location status: Recruiting

Location contact

Adam Wanner, MD

PRINCIPAL_INVESTIGATOR

Barry Hurwitz, MD

SUB_INVESTIGATOR

Michael Campos, MD

CONTACT

[email protected]

3052436388

Michael Campos, MD

SUB_INVESTIGATOR

Taghrid Asfar, MD

SUB_INVESTIGATOR

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Vapers Group:

  • Current electronic cigarette (EC) Puff Bar users defined as using EC either daily or occasionally in the past 30 days for at least 6 months, and with 5% nicotine concentration pods.
  • Adults aged 18-40 years

Healthy Group:

  • Healthy never smokers, never vapers
  • Adults aged 18-40 years

Exclusion criteria

  • Current or past smoking of tobacco cigarette (TC) or other tobacco/nicotine products (e.g., smokeless tobacco, Hookah) or marijuana will be excluded from the study.
  • Subjects with self-reported history of chronic health problems including asthma, chronic obstructive pulmonary disease (COPD), morbid obesity (BMI>40 kg/m2), hypertension or diabetes
  • Pregnant or breastfeeding women

Treatment and study plan

Primary outcomes

  1. Airway blood flow reactivity (QAW)

    Time frame: Up to 1 week

    QAW will be measured via soluble gas uptake method

  2. Pulmonary vascular resistance (PVR)

    Time frame: Up to 4 weeks

    PVR will be measured via echocardiography

  3. Flow-mediated vasodilation (FMD)

    Time frame: Up to 4 weeks

    FMD will be measured by blood pressure cuff deflation using ultrasound

Study contacts

Contact information is provided by the study sponsor or research team.

Adam Wanner, MD

CONTACT

[email protected]

(305)243-2568

Michael Campos, MD

CONTACT

[email protected]

3052436388

Sponsors and collaborators

Lead sponsor

University of Miami

Other

Collaborators

  • Florida Department of Health

Registry information

Acronym: ENDS

Important dates

Study start
2022
Primary completion
2027
Study completion
2027
First posted
Jul 12, 2022
Registry last updated
May 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.